Profound Medical Corp PROF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Profound Medical to Participate in the Stifel 2026 Healthcare Conference
Profound Medical Reports Strong Third Quarter 2026 Results; Expands U.S. Distribution and Positions Leadership for Next Phase of Growth
Profound Medical and Cook Medical’s iMRI Division Partner to Expand U.S. TULSA-PRO® Sales Channels and Drive Recurring Revenue Growth
Emmy-Award Winning Television Host Montel Williams to Join Next ‘Let’s Huddle’ Webinar
Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue
Profound Medical to Participate in Lake Street’s 10th Annual Best Ideas Growth Conference
Profound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as President
Trading Information
- Previous Close Price
- $7.44
- Day Range
- $7.20–7.63
- 52-Week Range
- $4.80–8.95
- Bid/Ask
- $7.39 / $7.68
- Shares Outstanding
- 36.63M
- Market Cap
- $271.77M
- Volume/Avg
- 95,853 / 207,520
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 10.97
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 162
Valuation
Metric | PROF |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.39 |
Price/Sales | 10.97 |
Price/Cash Flow | — |
Price/Earnings
PROF
Financial Strength
Metric | PROF |
|---|---|
Quick Ratio | 3.67 |
Current Ratio | 4.54 |
Interest Coverage | — |
Quick Ratio
PROF
Profitability
Metric | PROF |
|---|---|
Return on Assets (Normalized) | −47.57% |
Return on Equity (Normalized) | −59.63% |
Return on Invested Capital (Normalized) | −54.34% |
Return on Assets
PROF
Medical Devices Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Abbott Laboratories ABT | LOCK|VC<RRhz | LOCK|@NH! | $188B | |||
| Medtronic PLC MDT | LOCK|fsBGZlw | LOCK|@W#@q | $132B | |||
| Stryker Corp SYK | LOCK|HC@>Y#< | LOCK|c$m | $118B | |||
| Boston Scientific Corp BSX | LOCK|PSn>shD | LOCK|!ff@z | $64B | |||
| Edwards Lifesciences Corp EW | LOCK|zLqw>^rT | LOCK|nRhGk | $62B | |||
| GE HealthCare Technologies Inc Common Stock GEHC | LOCK|R@S!xZ | LOCK|s!C | $38B | |||
| DexCom Inc DXCM | LOCK|^&?Q!h@ | LOCK|sCTdt | $31B | |||
| Koninklijke Philips NV ADR PHG | LOCK|^FL | LOCK|J!< | $30B | |||
| Steris PLC STE | LOCK|K&KF$Pz | LOCK|nJnb | $26B | |||
| Zimmer Biomet Holdings Inc ZBH | LOCK|lc#kq#G | LOCK|Wc | $20B |
United States